SunTrust Banks Boosts AbbVie (ABBV) Price Target to $157.00

AbbVie (NYSE:ABBV) had its price objective increased by research analysts at SunTrust Banks to $157.00 in a research report issued to clients and investors on Monday, The Fly reports. The firm currently has an “average” rating on the stock. SunTrust Banks’ price objective points to a potential upside of 27.42% from the company’s previous close. SunTrust Banks also issued estimates for AbbVie’s Q4 2017 earnings at $1.45 EPS, FY2018 earnings at $6.66 EPS, FY2019 earnings at $8.04 EPS, FY2020 earnings at $9.22 EPS and FY2021 earnings at $10.15 EPS.

Other equities research analysts have also issued research reports about the stock. Leerink Swann lowered shares of AbbVie from an “outperform” rating to a “market perform” rating in a report on Monday. Zacks Investment Research cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets set a $66.00 target price on shares of AbbVie and gave the stock a “hold” rating in a research report on Friday, October 27th. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research report on Friday, October 13th. Finally, Barclays raised their target price on shares of AbbVie to $90.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $106.44.

Shares of AbbVie (NYSE ABBV) opened at $123.21 on Monday. The stock has a market cap of $196,696.13, a price-to-earnings ratio of 37.45, a price-to-earnings-growth ratio of 1.28 and a beta of 1.52. AbbVie has a twelve month low of $59.27 and a twelve month high of $125.86. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.44 by $0.04. The business had revenue of $7.74 billion for the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. The company’s revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.20 EPS. equities analysts expect that AbbVie will post 7.38 earnings per share for the current year.

In other AbbVie news, EVP Michael Severino sold 25,633 shares of AbbVie stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $94.69, for a total value of $2,427,188.77. Following the completion of the transaction, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at $10,881,964.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of AbbVie stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the transaction, the senior vice president now directly owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 476,376 shares of company stock valued at $45,580,873. 0.23% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Hudock Capital Group LLC grew its stake in shares of AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after acquiring an additional 806 shares during the period. Ffcm LLC grew its position in AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after buying an additional 963 shares during the period. Bristlecone Advisors LLC bought a new stake in AbbVie during the third quarter valued at approximately $113,000. BDO Wealth Advisors LLC bought a new stake in AbbVie during the second quarter valued at approximately $115,000. Finally, Hershey Trust Co. bought a new stake in AbbVie during the third quarter valued at approximately $139,000. 69.28% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/29/suntrust-banks-boosts-abbvie-abbv-price-target-to-157-00.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

The Fly

Analyst Recommendations for AbbVie (NYSE:ABBV)

Leave a Reply